Hostname: page-component-74656f9884-c52kr Total loading time: 0 Render date: 2026-11-07T22:02:34.865Z Has data issue: false hasContentIssue false
  • English
  • Français

Hypertrophic cardiomyopathy in Duchenne muscular dystrophy: a case series

Published online by Cambridge University Press:  13 November 2024

Eleanor Greiner Open the ORCID record for Eleanor Greiner [Opens in a new window] ,
Nobuyuki Ikeda ,
Thomas D. Ryan Open the ORCID record for Thomas D. Ryan [Opens in a new window]  and
Chet R. Villa
Eleanor Greiner
Affiliation:
The Heart Institute, Cincinnati Children’s Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA
Nobuyuki Ikeda
Affiliation:
The Heart Institute, Cincinnati Children’s Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA
Thomas D. Ryan
Affiliation:
The Heart Institute, Cincinnati Children’s Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA
Chet R. Villa*
Affiliation:
The Heart Institute, Cincinnati Children’s Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA
*
Corresponding author: Chet R. Villa; Email: Chet.villa@cchmc.org
Rights & Permissions [Opens in a new window]

Abstract

Duchenne muscular dystrophy is characterised by fibrofatty replacement of muscle, resulting in dilated cardiomyopathy. Hypertrophic cardiomyopathy affects 1:200–1:500 people and is characterised by asymmetric ventricular septal hypertrophy. To date, there have been two separately reported cases describing the combined pathology of these disorders. Herein, we expand upon these reports with a case series describing longitudinal findings in three patients with Duchenne muscular dystrophy who developed hypertrophic cardiomyopathy.

Keywords

Cardiomyopathymuscular dystrophyhypertrophy

Information

Type
Brief Report
Information
Cardiology in the Young , Volume 34 , Issue 10 , October 2024 , pp. 2272 - 2274
Check for updates
Copyright
© The Author(s), 2024. Published by Cambridge University Press

Introduction

Patient A

Patient A is a 16-year-old diagnosed with Duchenne muscular dystrophy at 3.5 years old in the setting of gross motor delays. He was started on daily corticosteroids (prednisone) at the time of diagnosis. At age 10, he developed late gadolinium enhancement in a typical Duchenne muscular dystrophy pattern and was prescribed spironolactone. He had normal biventricular size and systolic function. At age 12, an echocardiogram demonstrated new asymmetric septal hypertrophy with a left ventricular outflow tract peak gradient of 19 mmHg, systolic anterior motion of the mitral valve, and mild mitral regurgitation. His blood pressure was normal on multiple measurements. Subsequent MRI showed mid- and basal inferoseptal hypertrophy. These findings prompted genetic testing (Inviate HCM gene panel), which revealed a de novo pathologic variant in the MYBPC3 gene.

The patient’s current cardiac findings include a septal dimension of 1.5 cm at end-diastole (Figure 1a) with low-normal systolic function and progression of late gadolinium enhancement with septal sparing (Table 1). Over time, he has been maintained on spironolactone and metoprolol succinate. Angiotensin-converting enzyme inhibitors have been deferred due to his hypertrophy and outflow tract obstruction. He is now 17 years old, continues to ambulate short distances, and has no history of arrhythmia.

Figure 1.

a) Patient A. CMR at age 16 Maximal septal dimension of 1.5 cm. (b) Patient B. Echo at age 31 Maximal septal dimension 1.5 cm with an LVOT of 50 mmHg. (c)Patient C. CMR at age 19 Maximal septal dimension of 1.5 cm.

Table 1.

Patient data

HCM = Hypertrophic Cardiomyopathy; LVEF = Left Ventricular Ejection Fraction; LGE = Late Gadolinium Enhancement; NSVT = Non-Sustained Ventricular Tachycardia.

Patient B

Patient B is a 31-year-old diagnosed with Duchenne muscular dystrophy at age 4 in the setting of weakness and calf hypertrophy. He started daily corticosteroids (deflazacort) at age 8 with loss of ambulation at 19.5 years. He developed asymmetric septal hypertrophy on MRI at age 23. He had no systolic anterior motion of the mitral valve, mitral regurgitation, left ventricular outflow tract obstruction, or late gadolinium enhancement at the time. His blood pressure and biventricular function were normal. He subsequently underwent HCM-specific genetic testing which resulted in a variant of uncertain significance in TNNT2.

Since his clinical diagnosis, he has developed progressive hypertrophy with a maximum septal dimension of 1.5 cm at end-diastole (Figure 1b) with patchy late gadolinium enhancement. On his most recent echocardiogram, he was found to have a left ventricular outflow tract peak gradient of ∼50 mmHg with systolic anterior motion of the mitral valve and mild mitral regurgitation. His biventricular function remains normal. He has a history of non-sustained ventricular tachycardia on Holter monitoring at age 29 (Table 1). The family has deferred implantable cardioverter defibrillator given his relatively low arrhythmia burden and the anaesthesia considerations. From a medication perspective, he was on prophylactic lisinopril and carvedilol for a history of sinus tachycardia. The family elected to continue with each drug class over time, although the carvedilol was transitioned to metoprolol succinate given his left ventricular outflow tract obstruction. Spironolactone was added at age 30 after development of late gadolinium enhancement. The patient is currently 32 years old and doing well.

Patient C

Patient C was diagnosed with Duchenne muscular dystrophy at age 4 in the setting of gross motor difficulties. He was started on daily corticosteroids (deflazacort) at diagnosis and experienced loss of ambulation at 14.5 years of life. He developed late gadolinium enhancement in a typical distribution on MRI at age 10 and was started on lisinopril. At age 14, he developed asymmetric septal hypertrophy with maximal end-diastolic dimension of 1.29 cm (Z-score 3.3). He underwent HCM-specific genetic testing, which revealed a variant of uncertain significance in MYL2. The patient’s lisinopril was stopped as the risks were thought to outweigh the benefits given his newly diagnosed septal hypertrophy and no history of cardiac dysfunction. He was started on spironolactone at age 15 given development of late gadolinium enhancement, and metoprolol succinate at age 16 in the setting of hypertrophy and resting tachycardia. Lisinopril was restarted at age 17 due to progression of late gadolinium enhancement and new onset systolic dysfunction (left ventricular ejection fraction 50%). His systolic blood pressure remained largely age appropriate before and after initiation of these medications.

Over time, he had mild progression of his septal hypertrophy (maximum septal dimension 1.5 cm at end-diastole) but never developed left ventricular outflow tract obstruction or systolic anterior motion of the mitral valve (Figure 1c). He did have progression of late gadolinium enhancement (Table 1), but none in the areas of hypertrophy. He had normalisation of his cardiac function following re-initiation of lisinopril in his late teens. At age 20 he developed fever, cough and dyspnoea. Following intubation, he developed a large tension pneumothorax with hemodynamic compromise and death.

Discussion

Herein, we present a case series with follow-up of patients with Duchenne muscular dystrophy who developed features consistent with hypertrophic cardiomyopathy. One patient had genetic testing confirming a pathologic variant while the others had variants of uncertain significance in genes suspicious for involvement in hypertrophic cardiomyopathy on an Invitae HCM-specific genetic panel testing 26 specific genes known to be involved in HCM. None of the patients had a family history of cardiomyopathy or muscular dystrophy.

In Duchenne muscular dystrophy, the average age of onset for systolic dysfunction is ∼15.2 years with rate of decline ∼1–2% thereafter. Reference James, Gralla and Ridall1 In hypertrophic cardiomyopathy, ventricular function is characteristically normal. Reference Marstrand, Han and Day2 While all patients included in this series were older than 15 and had evidence of late gadolinium enhancement, ventricular systolic function was generally preserved (low-normal in patient A and transient, mild dysfunction in patient C). Similarly, the two previously published case reports describing similar dual-phenotype patients report normal or hyper-dynamic function in their patients (age 27 and 16 respectively). Reference Tandon, Taylor and Cripe3,Reference Aspit, Arwas, Krymko, Etzion, Parvari and Levitas4

Given function has been preserved, there was also appreciable concern for atrial and ventricular arrhythmias, which can occur in both hypertrophic cardiomyopathy and Duchenne muscular dystrophy. Reference Maron, Olivotto and Spirito5,Reference O’Mahony, Elliott and McKenna6 Regarding medical treatment, we have focused on a patient-guided approach especially for angiotensin-converting enzyme inhibitors. This class of medication is often used in the treatment of Duchenne muscular dystrophy but is generally contraindicated in patients with hypertrophic obstructive cardiomyopathy who have normal systolic function. Reference Ommen, Mital and Burke7 Our conversations have focused on the overall dystrophinopathy phenotype and severity of involvement given the lack of data regarding the optimal long-term approach. Similarly, the discussion regarding defibrillator placement in patient B, who has a class 2b indication for an implantable cardioverter defibrillator based on his history of non-sustained ventricular tachycardia and late gadolinium enhancement Reference Ommen, Mital and Burke7 has focused on balancing the risk of sudden death in hypertrophic cardiomyopathy with the patient’s dystrophinopathy phenotype and comorbidities.

Duchenne muscular dystrophy and hypertrophic cardiomyopathy are rare co-occurring disorders with varying clinical phenotypes requiring sometimes divergent clinical practices (e.g. use of afterload reducing agents). Given the population frequency of these conditions, individual cases will be rare, but not extremely so, given 1:500 people have hypertrophic cardiomyopathy. Reference Semsarian, Ingles, Maron and Maron8,Reference Longo and Maron9 Our clinical experience suggests it is reasonable to take a considered approach to therapy as the coexistence of these diseases does not dictate a uniformly worse prognosis.

Financial support

This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.

Competing interests

None.

References

James, KA, Gralla, J, Ridall, LA et al. Left ventricular dysfunction in Duchenne muscular Dystrophy. Cardiol Young 2020; 30: 171–176.CrossRefGoogle ScholarPubMed
Marstrand, P, Han, L, Day, SM et al. Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe registry. Circulation 2020; 141: 1371–1383.CrossRefGoogle ScholarPubMed
Tandon, A, Taylor, MD, Cripe, LH. Co-occurring duchenne muscular dystrophy and hypertrophic cardiomyopathy in an adult with atypical cardiac phenotype. Cardiol Young 2015; 25: 355–357.CrossRefGoogle Scholar
Aspit, L, Arwas, N, Krymko, H, Etzion, Y, Parvari, R, Levitas, A. Duchenne muscular dystrophy and early onset hypertrophic cardiomyopathy associated with mutations in dystrophin and hypertrophic cardiomyopathy-associated genes. J Pediatr Genet 2022; 11: 304–308.CrossRefGoogle ScholarPubMed
Maron, BJ, Olivotto, I, Spirito, P et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000; 102: 858–864.CrossRefGoogle Scholar
O’Mahony, C, Elliott, P, McKenna, W. Sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol 2013; 6: 443–451.CrossRefGoogle ScholarPubMed
Ommen, SR, Mital, S, Burke, MA et al. AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice guidelines. J Am Coll Cardiol 2020; 76: e159–e240.CrossRefGoogle Scholar
Semsarian, C, Ingles, J, Maron, MS, Maron, BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 2015; 65: 1249–1254.CrossRefGoogle ScholarPubMed
Longo, DL, Maron, BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 2018; 379: 655–668.Google Scholar
Figure 0

Figure 1. a) Patient A. CMR at age 16 Maximal septal dimension of 1.5 cm. (b) Patient B. Echo at age 31 Maximal septal dimension 1.5 cm with an LVOT of 50 mmHg. (c)Patient C. CMR at age 19 Maximal septal dimension of 1.5 cm.

Figure 1

Table 1. Patient data